BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32105979)

  • 1. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
    Antoni F; Bause M; Scholler M; Bauer S; Stark SA; Jackson SM; Manolaridis I; Locher KP; König B; Buschauer A; Bernhardt G
    Eur J Med Chem; 2020 Apr; 191():112133. PubMed ID: 32105979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach.
    Antoni F; Wifling D; Bernhardt G
    Eur J Med Chem; 2021 Jan; 210():112958. PubMed ID: 33199153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
    Puentes CO; Höcherl P; Kühnle M; Bauer S; Bürger K; Bernhardt G; Buschauer A; König B
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3654-7. PubMed ID: 21570282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
    Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
    J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
    Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
    ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2.
    Jackson SM; Manolaridis I; Kowal J; Zechner M; Taylor NMI; Bause M; Bauer S; Bartholomaeus R; Bernhardt G; Koenig B; Buschauer A; Stahlberg H; Altmann KH; Locher KP
    Nat Struct Mol Biol; 2018 Apr; 25(4):333-340. PubMed ID: 29610494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
    Krapf MK; Gallus J; Namasivayam V; Wiese M
    J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [
    Hernández Lozano I; Bauer M; Wulkersdorfer B; Traxl A; Philippe C; Weber M; Häusler S; Stieger B; Jäger W; Mairinger S; Wanek T; Hacker M; Zeitlinger M; Langer O
    Mol Pharm; 2020 Jan; 17(1):316-326. PubMed ID: 31790256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
    Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
    J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
    Tsunekawa R; Katayama K; Hanaya K; Higashibayashi S; Sugimoto Y; Sugai T
    Chembiochem; 2019 Jan; 20(2):210-220. PubMed ID: 30187992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
    Krapf MK; Gallus J; Spindler A; Wiese M
    Eur J Med Chem; 2019 Jan; 161():506-525. PubMed ID: 30390439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2.
    Kowal J; Ni D; Jackson SM; Manolaridis I; Stahlberg H; Locher KP
    J Mol Biol; 2021 Jun; 433(13):166980. PubMed ID: 33838147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
    Krapf MK; Gallus J; Wiese M
    Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
    Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
    Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
    Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS
    Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.